| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,940,000 |
| Market
Cap: |
202.02(M) |
| Last
Volume: |
38,851 |
Avg
Vol: |
19,585 |
| 52
Week Range: |
$1.63 - $1.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world.. In China, Co.'s first commercial product, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in our pipeline include: CNCT19, which is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
459,671 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,587,610 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Spectrum Pharmaceuticals Cayman, L.p. |
10% Owner |
– – • |
2016-02-22 |
4 |
B |
$0.01 |
$6,801 |
I/I |
680,113 |
2,856,868 |
1.5 |
- |
|
| Spectrum Pharmaceuticals Cayman, L.p. |
10% Owner |
– – • |
2016-02-22 |
4 |
B |
$0.01 |
$10,088 |
D/D |
1,008,764 |
4,237,391 |
2.37 |
- |
|
| Wong Cynthia |
COO |
• – – |
2016-01-19 |
4 |
B |
$0.72 |
$12,111 |
D/D |
16,800 |
17,785 |
2.74 |
- |
|
| Ren Ken Keyong |
CEO and Director |
• • – |
2016-01-19 |
4 |
B |
$0.71 |
$10,894 |
D/D |
15,000 |
15,000 |
2.81 |
- |
|
| Ren Ken |
CEO and Director |
• • – |
2016-01-19 |
4 |
B |
$0.71 |
$10,894 |
D/D |
15,000 |
15,000 |
2.81 |
- |
|
| Shong Hugo |
10% Owner |
– – • |
2016-01-14 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,744,910 |
|
- |
|
| Spectrum Pharmaceuticals Cayman, L.p. |
10% Owner |
– – • |
2014-09-17 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,176,755 |
|
- |
|
| Spectrum Pharmaceuticals Cayman, L.p. |
10% Owner |
– – • |
2014-09-17 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,228,627 |
|
- |
|
83 Records found
|
|
Page 4 of 4 |
|
|
